Comparing Olanzapine with Placebo in Patients with Anorexia Nervosa for Increasing BMI and Weight Gain

Jalal Jbara, Hedyeh Shaabani, Ekaterine Cherkezishvili, Siavash Hosseinpour Chermahini
{"title":"Comparing Olanzapine with Placebo in Patients with Anorexia Nervosa for Increasing BMI and Weight Gain","authors":"Jalal Jbara, Hedyeh Shaabani, Ekaterine Cherkezishvili, Siavash Hosseinpour Chermahini","doi":"10.11648/j.ajcem.20241201.12","DOIUrl":null,"url":null,"abstract":"Anorexia nervosa is an eating disorder characterized by exceptionally low body weight and a feeling of disgust toward food. In addition, it causes complications for the affected person as it affects their immunity, weakens them quickly, makes them sick and malnourished. The commonly known treatment for anorexia nervosa is psychological treatment using methods such as CBT and MANTRA. With the introduction of pharmacological medications, the aim of this review is now to determine whether olanzapine is effective compared to placebo in increasing BMI and weight gain. It was found that olanzapine had a large increase in BMI compared to placebo [F (1, 20) =6.64, p=0.018] and that it significantly reduced depression and anxiety. Further studies found that olanzapine patients gained weight more quickly and reached their BMI goals more quickly than patients taking a placebo. On the other hand, a contradictory result was found, namely that there was no significant difference between olanzapine and placebo in terms of weight recovery and psychological, depressive and anxiety symptoms. It is concluded that reliance on pharmacological therapies should be minimized until new evidence emerges and that psychotherapies such as CBT and MANTRA should be relied upon primarily to increase BMI in patients with anorexia nervosa.\n","PeriodicalId":404444,"journal":{"name":"American Journal of Clinical and Experimental Medicine","volume":"14 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical and Experimental Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11648/j.ajcem.20241201.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Anorexia nervosa is an eating disorder characterized by exceptionally low body weight and a feeling of disgust toward food. In addition, it causes complications for the affected person as it affects their immunity, weakens them quickly, makes them sick and malnourished. The commonly known treatment for anorexia nervosa is psychological treatment using methods such as CBT and MANTRA. With the introduction of pharmacological medications, the aim of this review is now to determine whether olanzapine is effective compared to placebo in increasing BMI and weight gain. It was found that olanzapine had a large increase in BMI compared to placebo [F (1, 20) =6.64, p=0.018] and that it significantly reduced depression and anxiety. Further studies found that olanzapine patients gained weight more quickly and reached their BMI goals more quickly than patients taking a placebo. On the other hand, a contradictory result was found, namely that there was no significant difference between olanzapine and placebo in terms of weight recovery and psychological, depressive and anxiety symptoms. It is concluded that reliance on pharmacological therapies should be minimized until new evidence emerges and that psychotherapies such as CBT and MANTRA should be relied upon primarily to increase BMI in patients with anorexia nervosa.
比较奥氮平与安慰剂对神经性厌食症患者增加体重指数和体重增加的作用
神经性厌食症是一种饮食失调症,其特征是体重特别低,对食物感到厌恶。此外,厌食症还会影响患者的免疫力,使其迅速虚弱、生病和营养不良,从而导致并发症。治疗神经性厌食症的常用方法是心理治疗,采用 CBT 和 MANTRA 等方法。随着药理药物的引入,本综述旨在确定奥氮平与安慰剂相比,在增加体重指数和体重增加方面是否有效。研究发现,与安慰剂相比,奥氮平可大幅增加体重指数[F(1,20)=6.64,P=0.018],并可显著减轻抑郁和焦虑。进一步的研究发现,与服用安慰剂的患者相比,奥氮平患者的体重增加更快,更快达到体重指数目标。另一方面,研究发现了一个矛盾的结果,即奥氮平与安慰剂在体重恢复、心理、抑郁和焦虑症状方面没有显著差异。结论是,在出现新的证据之前,应尽量减少对药物疗法的依赖,而应主要依靠 CBT 和 MANTRA 等心理疗法来提高神经性厌食症患者的体重指数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信